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Monoamine oxidase A is down-
regulated in eBV-associated 
nasopharyngeal carcinoma
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paul G. Murray7,8, Qian tao2, Ian C. paterson1,9 & Lee fah Yap1*
nasopharyngeal carcinoma (npc) is a highly metastatic cancer that is consistently associated with 
Epstein-Barr virus (EBV) infection. In this study, we identify for the first time a role for monoamine 
oxidase A (MAoA) in npc. MAoA is a mitochondrial enzyme that catalyzes oxidative deamination of 
neurotransmitters and dietary amines. Depending on the cancer type, MAOA can either have a tumour-
promoting or tumour-suppressive role. We show that MAOA is down-regulated in primary NPC tissues 
and its down-regulation enhances the migration of NPC cells. In addition, we found that EBV infection 
can down-regulate MAoA expression in both pre-malignant and malignant nasopharyngeal epithelial 
(NPE) cells. We further demonstrate that MAOA is down-regulated as a result of IL-6/IL-6R/STAT3 
signalling and epigenetic mechanisms, effects that might be attributed to EBV infection in NPE cells. 
Taken together, our data point to a central role for EBV in mediating the tumour suppressive effects of 
MAoA and that loss of MAoA could be an important step in the pathogenesis of npc.
Nasopharyngeal carcinoma (NPC) is a cancer with high invasive potential which is exceptionally common in 
Southern China and Southeast Asia1,2. Delayed presentation is a major challenge in NPC management with>75% 
of patients present with late stage disease1. A significant proportion of these patients (approximately 30%) develop 
distant metastases post therapy, which represents the major cause of death for NPC patients1,3. The mainstay of 
current treatment for advanced disease is restricted to concurrent chemoradiotherapy and regrettably, many NPC 
survivors suffer from an impaired health-related quality of life because the tumours are located in close proximity 
to many vital organs in the head and neck region4,5. Therefore, a better understanding of the molecular pathogen-
esis of NPC is essential to inform therapeutic interventions.
Undifferentiated type of NPC is invariably associated with Epstein-Barr virus (EBV) infection6. The impact 
of EBV infection on the development of NPC is thought to be a consequence of the aberrant establishment of 
virus latency in nasopharyngeal epithelial (NPE) cells displaying pre-malignant genetic changes (possibly as a 
result of exposure to environmental insults). Following infection, EBV induces additional changes resulting in 
the development of NPC. EBV latent gene expression in NPC is commonly restricted to Epstein-Barr nuclear 
antigen 1 (EBNA1), latent membrane proteins (LMP 1 and LMP2), EBV-encoded RNAs (EBERs) and BamHI-A 
transcripts. It is well established that many of the oncogenic effects of EBV in NPE cells can be attributed to its 
latent genes/proteins6. Although the association between EBV and NPC has been well-established, the exact con-
tribution of EBV to the cellular gene expression programme of NPC remains to be fully elucidated.
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Monoamine oxidase A (MAOA) is a mitochondrial enzyme that catalyzes the oxidative deamination of mono-
amine neurotransmitters (serotonin, norepinephrine and dopamine) and dietary amines (tyramine)7,8. The func-
tion of MAOA is well-defined in neurological disorders but its role in carcinogenesis appears to be more diverse9. 
An early study described the down-regulation of MAOA in multiple human cancer types10 and subsequently, a 
tumour-suppressive role of MAOA was reported in esophageal cancer11, cholangiocarcinoma12, hepatocellular 
carcinoma13 and breast cancer14. Conversely, tumour-promoting effects of MAOA have been described in prostate 
cancer15–18, and its overexpression was also reported in renal cell carcinoma19, glioma20 and non-small cell lung 
cancer21. Notably, MAOA was shown to be highly expressed in classical Hodgkin lymphoma (cHL), with expres-
sion more commonly seen in EBV-negative compared with EBV-positive cHL, especially in the EBV-negative 
nodular sclerosis subtype22. Here, we show for the first time that EBV infection down-regulates the expression 
of MAOA in pre-malignant and malignant NPE cells, possibly in part through IL-6/IL-6R signalling as well as 
epigenetic mechanisms. Importantly, we show that the down-regulation of MAOA enhances NPC cell migration. 
Taken together, our data provide evidence of a tumour-suppressive function for MAOA in EBV-associated NPC.
Results
Down-regulation of MAoA expression in npc. Re-analysis of two published microarray datasets, 
GSE1245223 and GSE3457324, revealed significant down-regulation of MAOA mRNA expression in the majority 
of micro-dissected NPC cells compared with normal epithelium (p < 0.01; Fig. 1A). MAOA mRNA expression 
in eight NPC cell lines (CNE1, CNE2, C666-1, HK1, HONE1, SUNE1, TW01 and TW04) was compared with 
that in three immortalised NPE cell lines, NP69, NP361hTert and NP460hTert. Compared to NP460hTert which 
is commonly used as a representative pre-malignant NPE cell line, seven NPC cell lines (CNE1, CNE2, C666-1, 
HONE1, SUNE1, TW01 and TW04) showed reduced levels of MAOA at both mRNA and protein levels (Fig. 1B). 
The expression and cellular localization of MAOA protein were then examined in archival formalin-fixed par-
affin-embedded (FFPE) NPC (n = 17) and non-cancerous nasopharyngeal tissues (n = 3) using immunohisto-
chemistry. As shown in Fig. 1C, MAOA expression was significantly reduced in NPC (mean H-score of 91, range 
0–290, mode 0, p < 0.0001) compared to normal and non-dysplastic surface epithelia (mean H-score of 278, 
range 190–300, mode 300). In 8 of 17 (47%) tumours, the H-score was 0. We conclude that MAOA is down-reg-
ulated in a subset of NPC.
MAoA inhibits npc cell migration. We next investigated if MAOA influences NPC cell behaviour in 
vitro, focussing on the migratory phenotype because distant metastasis remains a major cause of death for NPC 
patients. We used Transwell assays to examine the function of MAOA on the migration of NPC cells using two 
representative NPC cell lines (SUNE1 and HONE1). These cell lines were chosen based on the low endoge-
nous levels of MAOA in SUNE1 and detectable levels of MAOA in HONE1. SUNE1 cells were transduced with 
pEZ-lv105/MAOA or with the empty vector, and the increased expression of MAOA protein was confirmed 
(Fig. 2A). The results showed that ectopic expression of MAOA significantly suppressed the migration of SUNE1 
cells (p < 0.001; Fig. 2A). A complementary approach was performed in which MAOA was knocked down using 
siRNA in HONE1 cells and the reduced expression of MAOA protein was confirmed (Fig. 2B). In line with the 
data obtained from the ectopic expression experiments in SUNE1, knockdown of MAOA significantly increased 
the migration of HONE1 cells (p < 0.001; Fig. 2B).
eBV infection of npe cells decreases the expression of MAoA. Having shown that MAOA is 
down-regulated in NPC, we opted to investigate whether EBV infection could modulate MAOA levels in NPC 
cells. We first examined MAOA mRNA expression in six cell lines (NP460hTert, CNE1, CNE2, HK1, HONE1 
and SUNE1) stably infected with a recombinant EBV (Akata strain). We found that the levels of MAOA mRNA 
were significantly decreased in five cell lines (NP460hTert, CNE1, CNE2, HONE1 and SUNE1) infected with 
EBV with the exception of HK1 which was derived from a well-differentiated NPC tumour (p < 0.001; Fig. 3A). 
Among these cell lines, the reduction of MAOA protein expression was also evident in three EBV-infected cell 
lines (CNE2, HONE1 and NP460hTert) at the protein level (Fig. 3B). Despite being expressed at the mRNA level, 
MAOA protein was not detected in CNE1 and SUNE1 (Fig. 3B). Next, we investigated which EBV gene(s) were 
responsible for this effect. To do this, we examined MAOA expression in HONE1 cells individually transfected 
with the EBV genes, EBNA1, LMP1 or LMP2A, all of which are expressed in NPC in vivo. The expression of 
these genes in HONE1 cells was confirmed by RT-qPCR (Supplementary Fig. 2). We found that both the mRNA 
and protein levels of MAOA were down-regulated by EBNA1 and LMP2A, but not by LMP1, in HONE1 cells 
(Fig. 3C). These data indicate that EBV infection can reduce MAOA levels in both pre-malignant and malignant 
NPE cells in vitro.
IL-6/IL-6R/STAT3 inhibits MAOA expression. Having shown that EBV infection can reduce MAOA 
levels in NPC cells, we then investigated the mechanism of its down-regulation if this might be attributed to 
EBV infection. We focussed on the IL-6/IL-6R signalling because this pathway has been shown to inhibit MAOA 
expression in other cancer types12,14 and secondly, activation of this pathway has been reported in EBV-infected 
NPE cells and has been shown to promote their malignant properties, including migration25. In agreement 
with a previous report25, we showed that IL-6R mRNA expression was significantly increased in NP460hTert 
and HONE1 cells following EBV infection (p < 0.001; Fig. 4A). We investigated whether IL-6/IL-6R signal-
ling can modulate MAOA expression and we found that treatment of NP460hTert/EBV cells with IL-6 signifi-
cantly decreased the expression of MAOA (p < 0.001; Fig. 4B), an effect that was rescued by blocking the IL-6R 
(Fig. 4B). We next determined if the down-regulation of MAOA induced by IL-6/IL-6R signalling was mediated 
through STAT3. Activation of STAT3 was accompanied by the decreased MAOA expression in NP460hTert/
EBV cells treated with IL-6 and the expression of MAOA was restored with concomitant inhibition of STAT3 
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Figure 1. MAOA is down-regulated in NPC. (A) Two microarray datasets (GSE12452 and GSE34573) showed that 
MAOA mRNA was significantly down-regulated in micro-dissected NPC cells compared with normal epithelium 
(p < 0.01). (B) Compared to NP460hTert, MAOA mRNA and protein levels were decreased in seven (C666-1, CNE1, 
CNE2, HONE1, SUNE1, TW01 and TW04) out of eight NPC cell lines examined. Densitometric data are expressed 
as the relative density (normalized to β-actin). Full-length blots are presented in Supplementary Fig. S1. ***p < 0.001. 
(C) Immunohistochemical analysis of MAOA expression in primary NPC. (a,b): A case demonstrating positive 
MAOA staining. The adjacent normal epithelium (asterisk) and underlying islands of carcinoma (arrow) are both 
strongly positive; (c) High-power view of area highlighted by arrow in b. (d,e): A case demonstrating moderately 
positive MAOA staining of carcinoma (arrow) beneath the overlying epithelium (asterisk) that is strongly positive; 
(f) High-power view of area highlighted by arrow in e. (g,h): A case demonstrating negative MAOA staining. The 
adjacent normal epithelium (asterisk) is strongly positive whilst there is no staining in the carcinoma (arrow); (i) 
High-power view of area highlighted by arrow in h. Original magnification (a,d,g) ×40; (b,e,h) ×100; (c,f,i) ×400.
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phosphorylation following treatment with an IL-6R neutralising antibody (Fig. 4C). To further confirm the spec-
ificity of these effects, the cells were treated with a STAT3 inhibitor, Stattic, which also restored the expression 
of MAOA in NP460hTert/EBV cells (Fig. 4D). We conclude that IL-6/IL-6R/STAT3 can down-regulate MAOA 
expression and these effects could be attributed to EBV infection in NPE cells.
MAoA is down-regulated in npc partly through epigenetic silencing. Given that EBV infection 
induces DNA methylation in malignant epithelial cells26 and there is evidence showing that MAOA expression 
can be epigenetically regulated12, we next examined the methylation status of the MAOA promoter in NPC. The 
MAOA promoter region is a typical CpG island, and two pairs of MSP primers (m1/m2 and m9/m8) targeting 
different regions were designed (Fig. 5A). We used DNAs from a series of 54 primary NPC tissues which we have 
shown previously to be of good quality and suitable for MSP analyses27–30. MSP analyses using two different pairs 
of primers yielded similar results and methylation of the MAOA promoter was detected in 22 of 54 (40.7%) pri-
mary NPC tissues examined (Fig. 5B). In support of these data, the expression of MAOA was restored in SUNE1 
cells following the treatment with 5-aza-dC in the presence or absence of TSA (Fig. 5C). BSP analysis demon-
strated that the degree of methylation in the promoter of treated SUNE1 cells was generally lower than that in the 
untreated control (Fig. 5D). These findings indicate that epigenetic silencing is one of the mechanisms responsible 
for the low levels of MAOA expression in NPC.
Discussion
There is evidence to suggest that neurotransmitters are key players in the regulation of tumour cell migration, 
similar to the well-established effect of chemokines31. For example, it has been shown that norepinephrine and 
dopamine (substrates of MAOA) induced chemotaxis in breast cancer cells32. Although the role of such neuro-
transmitters in NPC is currently unknown, our results that show MAOA down-regulation promoting NPC cell 
migration supports these observations. Similarly, the reduced expression of MAOA has been shown to promote 
an invasive phenotype in cholangiocarcinoma, hepatocellular carcinoma and breast cancer12–14. Conversely, over-
expression of MAOA was reported in other cancer types, such as renal cell carcinoma, glioma, cHL, non-small 
cell lung cancer, and its oncogenic role is particularly well-described in prostate cancer, involving a ROS-activated 
AKT/FOXO/TWIST1 signalling pathway and maintenance of cancer stem cells9,19–22. Interestingly, a link between 
MAOA expression and EBV infection was implied by data showing that its expression was more commonly seen 
in EBV-negative than EBV-positive cHL and was particularly prevalent in the EBV-negative nodular sclerosis 
subtype22. In support of these observations, here we provide the first evidence to show that EBV infection can 
down-regulate MAOA in pre-malignant, as well as malignant NPE cells. We also noted that the expression of 
MAOA in HK1 cells (derived from a well-differentiated EBV-negative NPC tumour) was comparable to that of 
the NP460hTert cells, and its levels remained unchanged following EBV infection. Given that EBV infection can 
Figure 2. MAOA inhibits NPC cell migration. (A) Ectopic expression of MAOA significantly suppressed the 
migration of SUNE1 cells. Increased expression of MAOA was confirmed by Western blotting. (B) Inhibition 
of MAOA significantly enhanced the migration of HONE1 cells. Reduced levels of MAOA following siRNA 
treatment was confirmed by Western blotting. Full-length blots are presented in Supplementary Fig. S1. 
***p < 0.001.
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reduce MAOA expression even in the pre-malignant NPE cells, it suggests that such regulation is an early and 
crucial event in the pathogenesis of undifferentiated NPC. Nonetheless, we noted that MAOA was not reduced 
in all primary NPC examined, suggesting other carcinogenic mechanisms override the necessity for the loss of 
MAOA expression.
It is well-recognised that EBV infection alters multiple cellular signalling cascades that drive the progression 
and development of NPC. Constitutive activation of STAT3 is commonly reported in NPC33,34. IL-6 is a potent 
activator of STAT3 which binds to its cognate receptor on the cells membrane, IL-6R. Upon binding, Janus tyros-
ine kinases (JAKs) are activated and subsequently induce phosphorylation and dimerization of STAT335. Elevated 
levels of IL-6 were reported in sera of NPC patients and overexpression of IL-6R in primary NPC tissues25,36. 
Further, in vitro studies have shown that EBV infection of NPE cells led to the activation of the STAT3 pathway 
through IL-6/IL-6R signalling and this resulted in increased growth and invasive properties of NPE cells25,37. 
Down-regulation of MAOA by IL-6 or IL-6/IL-6R signalling has been inferred from a limited number of studies. 
The expression of MAOA is inhibited in chlorangiocarcinoma through IL-6 signalling via regulating the balance 
between SP-1 transcriptional activity (a positive regulator of MAOA) and its inhibitor, R1 repressor12. In breast 
cancer cells, activation of IL-6/IL-6R signalling suppressed MAOA expression in hypoxic environment14. We are 
the first to demonstrate that IL-6/IL-6R signalling down-regulates MAOA via the activation of STAT3, an effect 
that is likely attributable to EBV infection. Although we found that addition of IL-6 enhanced the migration of 
NP460hTert cells (Supplementary Fig. S3), we did not observe any increases in IL-6 levels following EBV infection 
of NP460hTert and HONE1 cells (data not shown). Our data suggest that the down-regulation of MAOA by IL-6/
IL-6R signalling in NP460hTert/EBV cells was mediated by the EBV-induced IL-6R overexpression.
Aberrant DNA methylation is one of the major epigenomic alterations that affect cancer development, leading 
to transcriptional silencing of tumour suppressor genes. The unique methylome of NPC and EBV-associated 
gastric cancer (EBVaGC) suggests the existence of an EBV-specific “epigenetic signature”30,38. Several EBV latent 
proteins can regulate multiple components of the cellular CpG methylation machinery, including DNA meth-
yltransferases (DNMTs), histone modifiers and chromatin remodelers26. LMP1 can upregulate the transcripts 
of DNMT1, DNMT3a and DNMT3b through the activation of JNK signalling in epithelial cells39. In EBVaGC, 
LMP2A is thought to induce the wide-spread hypermethylation by up-regulating cellular DMNT1 expression 
Figure 3. EBV infection down-regulates the expression of MAOA. (A) RT-qPCR analysis showed that 
the expression of MAOA was significantly reduced in an immortalised NPE cell line (NP460hTert) and 
four (CNE1, CNE2, HONE1, SUNE1) NPC cell lines stably infected with an Akata-derived recombinant 
EBV. Data are expressed as the relative expression between the cells infected with EBV and their respective 
controls (normalised to 1). (B) Western blot analysis showed that the protein levels of MAOA were reduced 
in NP460hTert and two NPC cell lines (CNE2 and HONE1) following EBV infection. (C) RT-qPCR and 
Western blotting analyses showed that both the mRNA and protein levels of MAOA were lower in HONE1 cells 
expressing specific EBV latent genes (EBNA1 or LMP2A) compared to the vector control cells. Full-length blots 
are presented in Supplementary Fig. S1. ***p < 0.001.
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through the activation of STAT3 signalling40. The ability of EBNA1 to interfere with HDAC3 was also evident in 
Burkitt lymphoma cells41. In the present study, we show that MAOA is down-regulated by EBNA1 and LMP2A 
in HONE1 cells and it is possible that these EBV genes modulate the cellular methylation machinery that results 
in MAOA reduction.
In conclusion, we report for the first time that MAOA is a putative tumour suppressor gene in NPC and its 
expression is regulated by EBV infection. Our data highlight the central role of EBV in the pathogenesis of NPC.
Materials and Methods
cell lines and tissue samples. A series of cell lines that included three immortalized NPE cell lines 
(NP69, NP361hTert, NP460hTert) and eight NPC-derived cell lines, seven of which are EBV-negative (CNE1, 
CNE2, HK1, HONE1, SUNE1, TW01 and TW04) and one is EBV-positive (C666-1), were used in this study. 
NPC cells stably infected with a recombinant EBV (Akata strain) or expressing individual EBV-encoded latent 
genes were generated as previously described42. Archival FFPE NPC and non-malignant nasopharyngeal tissues 
were obtained from the Sime Darby Medical Centre Subang Jaya, Malaysia. All samples were non-keratinising 
Figure 4. IL-6/IL-6R suppresses MAOA expression through STAT3. (A) Increased expression of IL-6R in 
NP460hTert and HONE1 cells following EBV infection. (B) Both the mRNA and protein levels of MAOA were 
decreased in NP460hTert/EBV following addition of IL-6 (50 ng/ml) and these effects were rescued by blocking 
IL-6R using an anti-IL-6R neutralizing antibody (1 µg/ml). (C) Following the addition of IL-6 in NP460hTert/
EBV, the decrease in MAOA levels was accompanied by the activation of STAT3 and the expression of MAOA 
was restored with concomitant inhibition of phosphorylated STAT3 following the treatment with an IL-6R 
neutralising antibody. (D) Treatment of NP460hTert with a STAT3 inhibitor, Stattic, restored the expression 
of MAOA. Densitometric data are expressed as the relative density (MAOA: normalized to β-actin; pSTAT3: 
normalized to total STAT3). Full-length blots are presented in Supplementary Fig. S1. ***p < 0.001.
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EBER-positive NPC. Ethical approval for this study was obtained from the Independent Ethics Committee, Sime 
Darby Healthcare, Malaysia (Ref # 201206.2).
Quantitative reverse transcription PCR (RT-qPCR). Expression of MAOA and IL-6R was examined 
by RT-qPCR as previously described43. Total RNA was extracted using a RNeasy Mini Kit (Qiagen, UK) and sub-
jected to reverse transcription using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, USA). 
Quantitative PCR was performed in triplicate using a QuantiNova SYBR Green PCR Kit (Qiagen) and an ABI 
Prism 7000 Sequence Detection System (Applied Biosystems). The primers used are listed in Table S1. GAPDH 
was amplified in the same reaction to serve as an internal control for normalization. Fold changes in gene expres-
sion were measured using the comparative threshold cycle method (ΔΔCt).
Figure 5. MAOA is down-regulated partly by epigenetic silencing. (A) A schematic diagram showing MAOA 
promoter region. Two pairs of MSP primers (m1/m2 and m9/m8) targeting different regions were designed. 
(B) MSP analyses using two different pairs of primers yielded similar results and methylation of MAOA 
promoter was detected in primary NPC tissues examined. Representative results are presented. Full-length gels 
are presented in Supplementary Fig. S1. (C) RT-qPCR and Western blotting analyses showed that treatment 
of SUNE1 cells with 5-Aza-dC restored the expression of MAOA and the levels were further increased in 
the presence of TSA. ***p < 0.001. Full-length blots are presented in Supplementary Fig. S1. (D) Bisulfite 
sequencing analysis showed that the degree of methylation in the promoter of 5-Aza-dC/TSA-treated SUNE1 
cells was generally lower than that in the untreated control.
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immunohistochemistry. Expression of MAOA proteins in primary NPC tissue samples was determined 
by immunohistochemistry using the DAKO REAL EnVision Detection System (DakoCytomation, Denmark) as 
described previously42. Anti-MAOA rabbit monoclonal antibody (Abcam, UK) was used at 1:150. Non-neoplastic 
tonsils demonstrating reactive lymphoid hyperplasia were used as positive controls. Immunohistochemical stain-
ing was evaluated semi-quantitatively using the H-score method. The percentage of tumour corresponding to an 
ordinal intensity value (0 = none, 1 = weak, 2 = moderate, 3 = strong) was assigned using whole sections. The 
H-score was defined as the sum of the percent of tumour cells staining multiplied by the intensity level, resulting 
in a score ranging from 0 (no staining in any of the tumour cells) to 300 (strong staining in all tumour cells). 
Where available, H-scoring was also undertaken for intra-sectional normal surface respiratory epithelium.
Western blotting. Protein expression of MAOA and STAT3 was examined by Western blotting as previously 
described43. Cells were lysed in ice-cold NP40 lysis buffer [150 mM NaCl, 1% IGEPAL CA-630, 50 mM Tris-HCl 
(pH 8.0)] containing protease inhibitors (cocktail set III; Calbiochem, Merck Millipore) and phosphatase inhib-
itors (Halt phosphatase inhibitor cocktail; Thermo Scientific, USA). Samples containing equal amounts of pro-
tein were separated under reducing conditions using SDS-PAGE and the proteins transferred to polyvinylidene 
difluoride membranes (Millipore, UK). The primary antibodies used in this study were anti-MAOA (1:1000; 
Abcam, UK), anti-phospho-STAT3 (Tyr705; 1:1000; Cell Signaling), anti-total STAT3 (1:1000; Cell Signaling) 
and anti-β-actin (1:5000; Sigma-Aldrich, USA). Bound antibodies were detected with peroxidase conjugated 
secondary antibodies and Enhanced Chemiluminescence reagents (Advansta, USA).
MAOA overexpression and knockdown. The expression plasmid carrying the coding region of MAOA, 
pEZ-lv105/MAOA, was kindly provided by Prof Zhi-Gang Zhang (Shanghai Cancer Institute Shanghai Jiao Tong 
University, Shanghai, China). Cells at 50% confluency were transfected with the pEZ-lv105/MAOA or the empty 
vector at a 3:1 FuGENE HD transfection reagent (Promega, USA):DNA ratio. Cells were used in Transwell migra-
tion assays 24 hours post-transfection. To knockdown MAOA, pre-designed RNAi SMART pool reagents for 
MAOA (L-009369–00) and non-targeting random siRNAs were obtained from Dharmacon, USA and used at 
25 nM. 5 × 105 cells were seeded into 100mm2 dishes, cultured for 16 hours and then transfected with the relevant 
siRNA using DharmaFECT 1 transfection reagent (Dharmacon, USA). Cells were used in Transwell migration 
assays 48 hours post-transfection.
transwell migration assays. Migration assays were carried out using fibronectin-coated (10 µg/ml) poly-
carbonate filters (8 µm pore size, Transwell, Corning). Cells were treated with mitomycin C for two hours prior 
to the experiments. 5 × 104 cells were seeded into the upper chamber and allowed to migrate for 19 hours in the 
presence of FBS (Gibco, USA) or IL-6 (Promokine, Germany) in the lower chamber. Migrated cells were stained 
with 0.1% crystal violet and counted in five random fields.
Methylation-specific PCR (MSP) and bisulphite sequencing (BSP). The protocols and DNA sam-
ples used for the MSP analysis have been previously described27–30. The modified DNA was amplified by PCR 
with methylated primers (Table S1). Universal methylated DNA was used as positive controls. To re-activate 
MAOA expression, SUNE-1 cells at 30% confluence were treated with the demethylation agent 5-aza-2′deoxycy-
tidine (5-aza-dC; Sigma-Aldrich, USA) for 4 days and/or a histone deacetylation inhibitor, Trichostatin A (TSA; 
Sigma-Aldrich) for the last 24 hours. For bisulphite sequencing, The DNA samples were subjected to bisulphite 
modification using the EZ DNA Methylation-Lightning Kit (Zymo Research, USA). A total of 12 CpG sites span-
ning the start codon of the MAOA promoter were analysed by bisulphite sequencing with primers designed using 
the MethPrimer software (Table S1).
Statistical analyses. All statistical analyses were performed using GraphPad Prism Version 5 (GraphPad 
Software Inc., USA). Statistical differences between experimental groups were evaluated by Student’s t-test or 
one-way analysis of variance (ANOVA)/Dunnett’s test. p-values <0.05 were regarded as significant.
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